Organization | Binzhou Medical University

Binzhou Medical University Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Yantai China (1970)

Organization Overview

First Clinical Trial

2015

NCT02415569

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Affiliated hospital of Binzhou | Binzhou Medical University | Binzhou Medical University Hospital | Binzhou People's Hospital

Active Ingredients

Drugs in Phase 4 Trials (13)

bisacodyl (Halflytely) (1 trial)

clarithromycin (biaxin) (1 trial)

furazolidone (furoxone) (1 trial)

ilaprazole (noltec) (1 trial)

levofloxacin (levaquin) (1 trial)

metronidazole (flagyl) (1 trial)

polyethylene glycol (2 trials)

procaine benzylpenicillin (novocaine) (1 trial)

prucalopride (1 trial)

tegafur (1 trial)

tetracycline (tetrex) (1 trial)

tinidazole (tindamax) (1 trial)

vitamin c (1 trial)

Drugs in Phase 3 Trials (2)

cytarabine (cytosar-u) (1 trial)

decitabine (dacogen) (1 trial)

Drugs in Other Trials (1)

ceftazidime (fortaz) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Disease Susceptibility (Phase 4)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial APIs: 16